Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Cytokinetics Inc., profitability ratios (quarterly data)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Cytokinetics Inc. operating profit margin ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Cytokinetics Inc. net profit margin ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Cytokinetics Inc. ROA deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Operating Profit Margin
Cytokinetics Inc., operating profit margin calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Operating income (loss) | (122,265) | (122,049) | (124,473) | (127,030) | (108,441) | (10,874) | (77,857) | (21,704) | (69,201) | (54,797) | (40,611) | (36,407) | 5,184) | (32,358) | (30,362) | (23,706) | (23,927) | (26,716) | (24,518) | (21,458) | (17,914) | (23,413) | (26,131) | |||||||
| Revenues | 378) | 867) | 4,613) | 1,957) | 2,515) | 88,968) | 1,148) | 55,600) | 5,437) | 2,843) | 6,548) | 6,722) | 41,688) | 3,593) | 3,825) | 5,212) | 6,055) | 7,137) | 8,464) | 9,377) | 10,641) | 6,215) | 5,268) | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| Operating profit margin1 | -6,344.43% | -4,843.18% | -378.18% | -342.75% | -147.66% | -118.84% | -343.79% | -264.54% | -932.79% | -219.08% | -177.95% | -168.27% | -149.57% | -590.60% | -471.06% | -367.97% | -311.34% | -254.38% | -251.62% | -282.26% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 27.32% | 31.03% | 28.49% | 31.21% | 30.59% | 30.33% | 32.68% | 31.89% | 30.09% | 28.95% | 23.63% | 24.81% | 28.45% | 30.17% | 39.86% | 39.03% | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 34.55% | 37.50% | 36.07% | 38.57% | 39.31% | 38.04% | 32.78% | 31.44% | 30.14% | 30.72% | 37.23% | 37.70% | 38.59% | 39.76% | 41.89% | 43.57% | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 16.96% | 17.29% | 18.13% | 17.96% | 19.04% | 18.19% | 16.79% | 15.91% | -15.73% | -17.02% | -19.19% | -21.60% | 9.27% | 11.67% | 16.30% | 22.62% | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 23.67% | 25.06% | 27.02% | 27.61% | 27.35% | 25.44% | 25.23% | 25.35% | 24.63% | 25.04% | 22.30% | 18.99% | 17.61% | 17.37% | 18.01% | 18.25% | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 18.42% | 24.17% | 22.45% | 24.97% | 24.65% | 25.50% | 25.94% | 22.45% | 23.17% | 21.81% | 22.06% | 24.69% | 23.55% | 24.48% | 25.64% | 22.29% | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 30.37% | 31.18% | 33.03% | 27.17% | 22.39% | 25.78% | 26.56% | 36.72% | 42.79% | 37.20% | 18.07% | 16.72% | 11.01% | -4.40% | 19.89% | 19.38% | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 25.55% | 25.61% | 25.21% | 24.63% | 23.89% | 23.47% | 23.76% | 24.95% | 24.69% | 25.23% | 24.10% | 23.60% | 24.30% | 24.64% | 25.62% | 24.15% | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 13.08% | 10.34% | 27.85% | 30.27% | 30.66% | 33.04% | 28.85% | 25.74% | 14.07% | 10.64% | 14.02% | 16.47% | 26.87% | 25.40% | 25.49% | 24.77% | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | -30.50% | 5.08% | 33.67% | 51.10% | 64.60% | 70.46% | 74.34% | 75.22% | 69.57% | 62.28% | 32.79% | -381.82% | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 13.44% | 27.69% | 34.30% | 34.83% | 33.59% | 30.37% | 26.12% | 23.91% | 24.67% | 24.12% | 21.20% | 19.47% | 21.17% | 21.17% | 24.20% | 25.46% | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 32.23% | 34.20% | 35.79% | 38.93% | 45.45% | 48.19% | 55.08% | 55.67% | 55.19% | 53.94% | 43.37% | 42.09% | 37.43% | 34.64% | 30.45% | 28.10% | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 15.81% | 15.42% | 16.29% | 18.69% | 20.54% | 22.51% | 23.83% | 25.57% | 27.04% | 28.00% | 27.68% | 24.19% | 20.90% | 17.05% | 17.86% | 17.99% | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Operating profit margin = 100
× (Operating income (loss)Q3 2023
+ Operating income (loss)Q2 2023
+ Operating income (loss)Q1 2023
+ Operating income (loss)Q4 2022)
÷ (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
= 100 × (-122,265 + -122,049 + -124,473 + -127,030)
÷ (378 + 867 + 4,613 + 1,957)
= -6,344.43%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Cytokinetics Inc. operating profit margin ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Net Profit Margin
Cytokinetics Inc., net profit margin calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Net loss | (129,422) | (128,637) | (131,289) | (137,380) | (142,310) | (19,820) | (89,445) | (30,570) | (76,086) | (61,554) | (47,104) | (43,930) | (3,175) | (40,780) | (39,405) | (30,640) | (29,573) | (32,113) | (29,366) | (26,468) | (22,017) | (27,523) | (30,281) | |||||||
| Revenues | 378) | 867) | 4,613) | 1,957) | 2,515) | 88,968) | 1,148) | 55,600) | 5,437) | 2,843) | 6,548) | 6,722) | 41,688) | 3,593) | 3,825) | 5,212) | 6,055) | 7,137) | 8,464) | 9,377) | 10,641) | 6,215) | 5,268) | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| Net profit margin1 | -6,739.96% | -5,422.19% | -439.35% | -411.21% | -190.34% | -142.85% | -396.22% | -305.72% | -1,061.13% | -269.48% | -230.55% | -228.00% | -209.88% | -751.39% | -592.61% | -452.93% | -378.69% | -308.72% | -303.70% | -337.41% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 11.81% | 15.50% | 13.37% | 20.39% | 23.19% | 22.04% | 22.00% | 20.54% | 13.66% | 12.40% | 10.28% | 10.08% | 18.16% | 19.20% | 24.77% | 23.69% | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 29.52% | 31.52% | 31.77% | 26.42% | 27.88% | 26.73% | 23.42% | 24.25% | 23.03% | 23.80% | 29.60% | 29.97% | 30.91% | 31.53% | 33.64% | 35.32% | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 18.44% | 17.62% | 15.95% | 13.71% | 14.29% | 14.04% | 13.31% | 15.08% | -11.89% | -11.44% | -14.53% | -21.20% | -0.11% | -1.61% | 3.08% | 13.15% | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 21.83% | 22.80% | 23.32% | 22.91% | 21.65% | 20.61% | 21.32% | 21.84% | 20.97% | 21.00% | 19.17% | 16.36% | 18.05% | 18.35% | 18.13% | 16.80% | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 15.55% | 22.01% | 20.54% | 21.88% | 20.63% | 19.58% | 20.90% | 19.71% | 21.52% | 22.71% | 23.91% | 25.24% | 24.01% | 24.48% | 23.97% | 37.27% | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 21.60% | 20.18% | 20.87% | 17.02% | 12.44% | 15.22% | 16.60% | 23.05% | 27.21% | 19.62% | 1.19% | 0.51% | 5.56% | -1.18% | 22.17% | 24.35% | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 39.58% | 14.52% | 13.77% | 18.90% | 19.95% | 19.21% | 20.90% | 22.26% | 19.55% | 19.92% | 17.95% | 17.82% | 21.01% | 18.86% | 20.75% | 18.42% | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 7.77% | 5.34% | 22.52% | 24.49% | 25.88% | 29.00% | 26.27% | 26.79% | 15.09% | 11.83% | 15.09% | 14.72% | 24.33% | 22.20% | 21.10% | 21.01% | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | -39.67% | 11.95% | 33.37% | 45.36% | 57.36% | 63.31% | 66.94% | 69.04% | 64.55% | 57.01% | 30.95% | -373.77% | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 15.29% | 27.55% | 31.25% | 31.27% | 29.81% | 28.94% | 27.01% | 27.04% | 28.77% | 23.86% | 24.03% | 22.95% | 18.59% | 31.31% | 32.32% | 31.45% | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 30.47% | 33.93% | 33.81% | 35.64% | 39.17% | 39.97% | 48.06% | 50.25% | 51.65% | 50.11% | 43.53% | 41.35% | 38.28% | 37.30% | 28.56% | 26.91% | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 13.68% | 13.14% | 13.75% | 15.47% | 15.92% | 17.37% | 18.49% | 19.70% | 21.93% | 22.47% | 22.08% | 19.79% | 17.12% | 14.12% | 14.31% | 14.47% | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Net profit margin = 100
× (Net lossQ3 2023
+ Net lossQ2 2023
+ Net lossQ1 2023
+ Net lossQ4 2022)
÷ (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
= 100 × (-129,422 + -128,637 + -131,289 + -137,380)
÷ (378 + 867 + 4,613 + 1,957)
= -6,739.96%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Cytokinetics Inc. net profit margin ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Return on Equity (ROE)
Cytokinetics Inc., ROE calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Net loss | (129,422) | (128,637) | (131,289) | (137,380) | (142,310) | (19,820) | (89,445) | (30,570) | (76,086) | (61,554) | (47,104) | (43,930) | (3,175) | (40,780) | (39,405) | (30,640) | (29,573) | (32,113) | (29,366) | (26,468) | (22,017) | (27,523) | (30,281) | |||||||
| Stockholders’ equity (deficit) | (438,801) | (333,115) | (229,020) | (107,900) | (15,977) | 111,414) | 116,261) | 243,863) | 249,020) | 16,489) | 67,846) | 113,383) | 149,605) | (78,080) | (45,711) | (10,937) | (19,869) | (4,896) | 3,372) | 25,934) | 52,069) | 75,170) | 99,599) | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| ROE1 | — | — | — | — | — | -193.80% | -221.62% | -88.29% | -91.83% | -944.65% | -198.96% | -112.27% | -76.20% | — | — | — | — | — | -3,124.97% | -409.84% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 53.86% | 67.50% | 57.14% | 68.60% | 83.83% | 86.24% | 76.64% | 74.91% | 55.60% | 53.01% | 37.63% | 35.30% | 48.34% | 47.30% | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 98.82% | 117.67% | 148.04% | 178.97% | 187.11% | 271.85% | 624.78% | 87.96% | 68.26% | 69.67% | 75.91% | 77.20% | 67.09% | 68.48% | 80.92% | 81.07% | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 28.57% | 24.91% | 22.97% | 20.37% | 20.44% | 20.30% | 19.79% | 19.46% | -14.52% | -13.80% | -16.54% | -23.84% | -0.09% | -1.15% | 1.91% | 6.66% | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 11.29% | 12.30% | 13.47% | 14.39% | 14.40% | 13.63% | 13.93% | 14.24% | 13.54% | 13.12% | 11.76% | 9.17% | 9.70% | 9.56% | 10.53% | 9.94% | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 44.46% | 58.73% | 50.82% | 58.64% | 59.91% | 66.61% | 65.69% | 62.16% | 76.99% | 94.20% | 88.31% | 109.79% | 115.45% | 137.26% | 179.72% | 319.09% | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 26.33% | 25.92% | 26.59% | 21.62% | 15.82% | 20.44% | 22.66% | 29.55% | 34.44% | 26.20% | 1.59% | 0.68% | 7.27% | -1.43% | 22.49% | 23.91% | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 48.61% | 17.37% | 17.95% | 23.36% | 25.68% | 24.05% | 26.54% | 28.20% | 25.44% | 25.53% | 22.96% | 23.25% | 26.35% | 24.11% | 28.01% | 25.42% | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 11.17% | 8.04% | 27.82% | 31.57% | 34.32% | 38.34% | 34.68% | 34.17% | 20.10% | 16.73% | 26.08% | 27.91% | 39.47% | 37.91% | 38.72% | 37.99% | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | -25.76% | 7.12% | 25.36% | 43.73% | 65.39% | 78.15% | 85.73% | 86.26% | 69.75% | 52.13% | 15.59% | -29.17% | -21.66% | -16.54% | -30.82% | -43.75% | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 10.81% | 21.68% | 28.77% | 32.79% | 32.14% | 33.61% | 30.29% | 28.47% | 26.28% | 18.86% | 16.23% | 15.21% | 12.22% | 22.05% | 24.21% | 25.77% | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 16.03% | 17.90% | 17.80% | 19.14% | 25.05% | 27.49% | 39.84% | 43.03% | 40.53% | 41.02% | 33.43% | 31.86% | 31.17% | 32.94% | 18.79% | 19.08% | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 13.11% | 13.08% | 14.26% | 15.80% | 16.15% | 17.59% | 18.56% | 18.94% | 22.13% | 23.32% | 22.60% | 18.47% | 15.33% | 12.41% | 12.85% | 12.45% | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
ROE = 100
× (Net lossQ3 2023
+ Net lossQ2 2023
+ Net lossQ1 2023
+ Net lossQ4 2022)
÷ Stockholders’ equity (deficit)
= 100 × (-129,422 + -128,637 + -131,289 + -137,380)
÷ -438,801 = —
2 Click competitor name to see calculations.
Return on Assets (ROA)
Cytokinetics Inc., ROA calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Net loss | (129,422) | (128,637) | (131,289) | (137,380) | (142,310) | (19,820) | (89,445) | (30,570) | (76,086) | (61,554) | (47,104) | (43,930) | (3,175) | (40,780) | (39,405) | (30,640) | (29,573) | (32,113) | (29,366) | (26,468) | (22,017) | (27,523) | (30,281) | |||||||
| Total assets | 740,614) | 779,899) | 889,815) | 1,014,775) | 1,075,961) | 771,717) | 856,253) | 841,319) | 827,539) | 564,302) | 577,062) | 533,803) | 474,112) | 232,495) | 256,582) | 289,814) | 187,393) | 198,218) | 198,611) | 211,178) | 230,279) | 247,239) | 279,926) | |||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||
| ROA1 | -71.12% | -69.19% | -48.41% | -38.33% | -26.22% | -27.98% | -30.09% | -25.59% | -27.63% | -27.60% | -23.39% | -23.85% | -24.04% | -60.39% | -51.34% | -41.99% | -62.71% | -55.48% | -53.06% | -50.33% | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 4.78% | 6.42% | 5.64% | 8.53% | 9.49% | 8.83% | 8.71% | 7.88% | 5.06% | 4.50% | 3.43% | 3.07% | 4.93% | 4.65% | 9.25% | 8.84% | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 8.36% | 8.84% | 8.92% | 10.06% | 10.73% | 11.09% | 9.67% | 9.63% | 8.63% | 9.61% | 11.33% | 11.54% | 11.37% | 11.23% | 12.45% | 13.13% | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 9.08% | 8.52% | 7.75% | 6.53% | 6.80% | 6.59% | 6.07% | 6.40% | -4.87% | -4.58% | -5.53% | -7.61% | -0.04% | -0.44% | 0.74% | 2.65% | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 6.74% | 7.49% | 8.15% | 8.55% | 8.35% | 7.76% | 7.74% | 7.73% | 7.13% | 7.19% | 6.30% | 4.79% | 5.05% | 4.86% | 4.74% | 4.85% | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 8.61% | 11.85% | 10.70% | 12.62% | 12.71% | 12.09% | 13.06% | 11.44% | 12.39% | 12.70% | 13.01% | 13.28% | 12.68% | 13.39% | 13.46% | 21.17% | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 9.42% | 8.80% | 9.02% | 7.27% | 5.33% | 6.58% | 7.16% | 9.16% | 11.02% | 7.59% | 0.45% | 0.18% | 2.08% | -0.46% | 8.31% | 8.74% | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 20.85% | 6.81% | 6.49% | 9.57% | 10.94% | 10.33% | 11.12% | 11.47% | 9.98% | 10.07% | 8.76% | 8.41% | 9.95% | 9.59% | 11.07% | 9.59% | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 4.32% | 2.98% | 12.09% | 13.30% | 14.25% | 15.48% | 13.29% | 12.35% | 7.70% | 6.14% | 7.73% | 7.72% | 12.83% | 11.56% | 11.95% | 11.66% | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | -17.82% | 5.52% | 19.83% | 32.34% | 45.15% | 53.97% | 53.02% | 49.46% | 33.75% | 21.64% | 4.71% | -10.18% | -12.85% | -13.98% | -24.46% | -32.34% | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 4.87% | 9.75% | 14.85% | 15.91% | 15.32% | 15.01% | 13.58% | 12.11% | 11.10% | 7.78% | 7.01% | 6.23% | 4.46% | 7.97% | 9.47% | 9.72% | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 12.41% | 14.02% | 13.91% | 14.85% | 19.40% | 20.90% | 30.11% | 31.75% | 29.55% | 28.88% | 22.53% | 20.47% | 19.62% | 20.68% | 14.46% | 14.29% | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 6.12% | 6.08% | 6.36% | 7.15% | 7.77% | 8.21% | 8.20% | 8.12% | 11.64% | 12.70% | 12.02% | 9.23% | 7.62% | 6.02% | 6.25% | 6.33% | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
ROA = 100
× (Net lossQ3 2023
+ Net lossQ2 2023
+ Net lossQ1 2023
+ Net lossQ4 2022)
÷ Total assets
= 100 × (-129,422 + -128,637 + -131,289 + -137,380)
÷ 740,614 = -71.12%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Cytokinetics Inc. ROA deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |